Insulet (NSDQ:PODD) posted its fourth-quarter and full-year financial results yesterday after the markets closed, beating estimates on Wall Street.
The Acton, Mass.-based company posted profits of $9.9 million, or 17¢ per share, on sales of $164.9 million for the three months ended Dec. 31. It was the first time in the company’s history that it recorded a quarterly profit rather than a net loss. Q4 sales were up 26% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Insulet tops estimates with Q4 results appeared first on MassDevice.